The effect of travoprost on daytime intraocular pressure in normal-tension glaucoma: a randomised controlled trial
- Ghee Soon Ang (gsang1{at}doctors.org.uk),
- James P Kersey (james.kersey{at}rbch.nhs.uk),
- Lee Shepstone (l.shepstone{at}uea.ac.uk),
- David C Broadway (david.broadway{at}nnuh.nhs.uk)
- NHS Grampian, Aberdeen Royal Infirmary, United Kingdom
- Norfolk & Norwich University Hospital, United Kingdom
- University of East Anglia, United Kingdom
- Norfolk & Norwich University Hospital, United Kingdom
- Published Online First 29 May 2008
Abstract
Background / Aims To determine the medium-term effect of travoprost on the daytime intraocular pressure (IOP) of patients with normal tension glaucoma (NTG)
Methods Newly diagnosed NTG patients underwent baseline, daytime, hourly IOP phasing. Patients were randomised to either treatment or no treatment (control). Treatment comprised once daily topical travoprost 0.004%. After 6 months, the participants underwent their second IOP phasing.
Results Data from 88 participants were analysed - 54 were randomised to treatment and 34 to the control group. The average duration of treatment was 6 months. The mean, maximum and minimum diurnal IOPs for treated patients were statistically significantly lower than for control patients at follow-up (p<0.001). When compared to baseline IOP, the travoprost treated group demonstrated a decrease of 16.1%, 13.5% and 16.7% in the average IOP, maximum IOP, and minimum IOP respectively. Of those treated, about one-third achieved an IOP decrease in mean IOP of at least 20%; only about one-tenth achieved a reduction of at least 30%.
Conclusion Travoprost monotherapy had a sustained hypotensive effect in NTG and achieved a reasonable or good response (>20% reduction in mean IOP) in 32.9% of treated eyes. However, in the majority of eyes with NTG, travoprost monotherapy appeared unable to produce the desirable 30% reduction in mean IOP.
